| Terri Steddum, OD | |
|
15702 E State Highway 9, Norman, OK 73026-9001 | |
| (405) 447-0300 | |
| Not Available |
| Full Name | Terri Steddum |
|---|---|
| Gender | Female |
| Speciality | Optometry |
| Experience | 17 Years |
| Location | 15702 E State Highway 9, Norman, Oklahoma |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1093905614 | NPI | - | NPPES |
| 2543 | Other | OK | STATE LICENSE NUMBER |
| 800522350 | Other | OK | MEDICARE GROUP |
| 200116210A | Medicaid | OK | |
| 2700 | Other | CO | STATE LICENSE NUMBER |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 152W00000X | Optometrist | 2543 (Oklahoma) | Primary |
| 152W00000X | Optometrist | 2700 (Colorado) | Secondary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Guthrie Vision Source Pc Inc | 7416905237 | 3 |
News Archive
Middle East respiratory syndrome (MERS) has recently returned to the headlines as new cases have been exported to Korea and China. Experts are concerned that MERS cases continued to be detected in Saudi Arabia throughout the past year, and there appears to be little reduction in the number of cases since its first discovery three years ago. As the month of Ramadan approaches, with 1 million pilgrims expected to arrive in Saudi Arabia in June and July 2015, MERS remains a threat to global health security.
Yesterday, at the SPSS Directions 2009 North American Conference in Las Vegas, Nev., David Mould, Ph.D., predictive analytics scientist at MedeAnalytics, delivered a presentation to business executives, IT professionals, and researchers on ways MedeAnalytics uses cloud computing, also known as SaaS (Software-as-a-Service), to provide clients with advanced analytic tools and solutions.
GlaxoSmithKline announced today that the U.S. Centers for Disease Control and Prevention's (CDC's) Advisory Committee on Immunization Practices (ACIP) recommended that CERVARIX® [Human papillomavirus bivalent (types 16 and 18) vaccine, recombinant] be given to girls and young women to protect against cervical pre-cancers and cervical cancer caused by oncogenic HPV 16 and 18.
Mylan Pharmaceuticals Inc. has received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Applications (ANDAs) for Ondansetron Hydrochloride (HCl) Tablets, 4 mg (base), 8 mg (base) and 24 mg (base), and Ondansetron Orally Disintegrating Tablets (ODT) USP, 4 mg and 8 mg.
› Verified 5 days ago
| Provider Name | Guthrie Vision Source Pc Inc |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1982625703 PECOS PAC ID: 7416905237 Enrollment ID: O20050108000164 |
News Archive
Middle East respiratory syndrome (MERS) has recently returned to the headlines as new cases have been exported to Korea and China. Experts are concerned that MERS cases continued to be detected in Saudi Arabia throughout the past year, and there appears to be little reduction in the number of cases since its first discovery three years ago. As the month of Ramadan approaches, with 1 million pilgrims expected to arrive in Saudi Arabia in June and July 2015, MERS remains a threat to global health security.
Yesterday, at the SPSS Directions 2009 North American Conference in Las Vegas, Nev., David Mould, Ph.D., predictive analytics scientist at MedeAnalytics, delivered a presentation to business executives, IT professionals, and researchers on ways MedeAnalytics uses cloud computing, also known as SaaS (Software-as-a-Service), to provide clients with advanced analytic tools and solutions.
GlaxoSmithKline announced today that the U.S. Centers for Disease Control and Prevention's (CDC's) Advisory Committee on Immunization Practices (ACIP) recommended that CERVARIX® [Human papillomavirus bivalent (types 16 and 18) vaccine, recombinant] be given to girls and young women to protect against cervical pre-cancers and cervical cancer caused by oncogenic HPV 16 and 18.
Mylan Pharmaceuticals Inc. has received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Applications (ANDAs) for Ondansetron Hydrochloride (HCl) Tablets, 4 mg (base), 8 mg (base) and 24 mg (base), and Ondansetron Orally Disintegrating Tablets (ODT) USP, 4 mg and 8 mg.
› Verified 5 days ago
| Provider Name | Li-si-wi-nwi Health, Inc |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1124152962 PECOS PAC ID: 4183895519 Enrollment ID: O20130227000474 |
News Archive
Middle East respiratory syndrome (MERS) has recently returned to the headlines as new cases have been exported to Korea and China. Experts are concerned that MERS cases continued to be detected in Saudi Arabia throughout the past year, and there appears to be little reduction in the number of cases since its first discovery three years ago. As the month of Ramadan approaches, with 1 million pilgrims expected to arrive in Saudi Arabia in June and July 2015, MERS remains a threat to global health security.
Yesterday, at the SPSS Directions 2009 North American Conference in Las Vegas, Nev., David Mould, Ph.D., predictive analytics scientist at MedeAnalytics, delivered a presentation to business executives, IT professionals, and researchers on ways MedeAnalytics uses cloud computing, also known as SaaS (Software-as-a-Service), to provide clients with advanced analytic tools and solutions.
GlaxoSmithKline announced today that the U.S. Centers for Disease Control and Prevention's (CDC's) Advisory Committee on Immunization Practices (ACIP) recommended that CERVARIX® [Human papillomavirus bivalent (types 16 and 18) vaccine, recombinant] be given to girls and young women to protect against cervical pre-cancers and cervical cancer caused by oncogenic HPV 16 and 18.
Mylan Pharmaceuticals Inc. has received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Applications (ANDAs) for Ondansetron Hydrochloride (HCl) Tablets, 4 mg (base), 8 mg (base) and 24 mg (base), and Ondansetron Orally Disintegrating Tablets (ODT) USP, 4 mg and 8 mg.
› Verified 5 days ago
| Provider Name | Absentee Shawnee Tribal Health Authority, Inc |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1942253521 PECOS PAC ID: 5799171088 Enrollment ID: O20220414000294 |
News Archive
Middle East respiratory syndrome (MERS) has recently returned to the headlines as new cases have been exported to Korea and China. Experts are concerned that MERS cases continued to be detected in Saudi Arabia throughout the past year, and there appears to be little reduction in the number of cases since its first discovery three years ago. As the month of Ramadan approaches, with 1 million pilgrims expected to arrive in Saudi Arabia in June and July 2015, MERS remains a threat to global health security.
Yesterday, at the SPSS Directions 2009 North American Conference in Las Vegas, Nev., David Mould, Ph.D., predictive analytics scientist at MedeAnalytics, delivered a presentation to business executives, IT professionals, and researchers on ways MedeAnalytics uses cloud computing, also known as SaaS (Software-as-a-Service), to provide clients with advanced analytic tools and solutions.
GlaxoSmithKline announced today that the U.S. Centers for Disease Control and Prevention's (CDC's) Advisory Committee on Immunization Practices (ACIP) recommended that CERVARIX® [Human papillomavirus bivalent (types 16 and 18) vaccine, recombinant] be given to girls and young women to protect against cervical pre-cancers and cervical cancer caused by oncogenic HPV 16 and 18.
Mylan Pharmaceuticals Inc. has received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Applications (ANDAs) for Ondansetron Hydrochloride (HCl) Tablets, 4 mg (base), 8 mg (base) and 24 mg (base), and Ondansetron Orally Disintegrating Tablets (ODT) USP, 4 mg and 8 mg.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Terri Steddum, OD 15951 Little Axe Dr, Norman, OK 73026-9088 Ph: (405) 447-0300 | Terri Steddum, OD 15702 E State Highway 9, Norman, OK 73026-9001 Ph: (405) 447-0300 |
News Archive
Middle East respiratory syndrome (MERS) has recently returned to the headlines as new cases have been exported to Korea and China. Experts are concerned that MERS cases continued to be detected in Saudi Arabia throughout the past year, and there appears to be little reduction in the number of cases since its first discovery three years ago. As the month of Ramadan approaches, with 1 million pilgrims expected to arrive in Saudi Arabia in June and July 2015, MERS remains a threat to global health security.
Yesterday, at the SPSS Directions 2009 North American Conference in Las Vegas, Nev., David Mould, Ph.D., predictive analytics scientist at MedeAnalytics, delivered a presentation to business executives, IT professionals, and researchers on ways MedeAnalytics uses cloud computing, also known as SaaS (Software-as-a-Service), to provide clients with advanced analytic tools and solutions.
GlaxoSmithKline announced today that the U.S. Centers for Disease Control and Prevention's (CDC's) Advisory Committee on Immunization Practices (ACIP) recommended that CERVARIX® [Human papillomavirus bivalent (types 16 and 18) vaccine, recombinant] be given to girls and young women to protect against cervical pre-cancers and cervical cancer caused by oncogenic HPV 16 and 18.
Mylan Pharmaceuticals Inc. has received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Applications (ANDAs) for Ondansetron Hydrochloride (HCl) Tablets, 4 mg (base), 8 mg (base) and 24 mg (base), and Ondansetron Orally Disintegrating Tablets (ODT) USP, 4 mg and 8 mg.
› Verified 5 days ago
Family Vision Trends Llc Optometrist Medicare: Medicare Enrolled Practice Location: 1021 24th Ave Nw, Norman, OK 73069 Phone: 405-329-3937 Fax: 405-329-3556 | |
Tanya Ingels, O.D. Optometrist Medicare: Not Enrolled in Medicare Practice Location: 3720 W Robinson St, Suite 118, Norman, OK 73072 Phone: 405-447-5001 Fax: 405-447-4680 | |
Dr. Priya Filinto Moore, Optometrist Medicare: Accepting Medicare Assignments Practice Location: 1021 24th Ave Nw, Norman, OK 73069 Phone: 405-329-3937 | |
Dr. Jay D. Johnson, OD Optometrist Medicare: Accepting Medicare Assignments Practice Location: 1120 Rambling Oaks Drive, Norman, OK 73072 Phone: 405-701-4114 Fax: 405-801-3689 | |
Dr. Kalyn Dawn Austin, OD Optometrist Medicare: Accepting Medicare Assignments Practice Location: 1369 24th Ave Nw, Norman, OK 73069 Phone: 405-366-1110 | |
Joel C Razook, Md Pc Optometrist Medicare: Not Enrolled in Medicare Practice Location: 2300 36th Ave Nw, Suite 110, Norman, OK 73072 Phone: 405-579-7664 Fax: 405-321-3193 |